Authors: Bachelot, T Ray-Coquard, I Catimel, G Ardiet, C Guastalla, JP Dumortier, A Chauvin, F Droz, JP Philip, T Clavel, M

Citation: T. Bachelot et al., Multivariable analysis of prognostic factors for toxicity and survival forpatients enrolled in phase I clinical trials, ANN ONCOL, 11(2), 2000, pp. 151-156

Authors: Schrijvers, D Catimel, G Highley, M Hoppener, FJP Dirix, L De Bruijn, E Droz, JP Van Oosterom, AT

Citation: D. Schrijvers et al., KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study, ANTI-CANC D, 10(7), 1999, pp. 633-639

Authors: Planting, AST Catimel, G de Mulder, PHM de Graeff, A Hoppener, F Verweij, J Oster, W Vermorken, JB

Citation: Ast. Planting et al., Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer, ANN ONCOL, 10(6), 1999, pp. 693-700

Authors: Schoffski, P Catimel, G Planting, AST Droz, JP Verweij, J Schrijvers, D Gras, L Schrijvers, A Wanders, J Hanauske, AR

Citation: P. Schoffski et al., Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck - Results of a phase II study of the EORTC Early Clinical Studies Group, ANN ONCOL, 10(1), 1999, pp. 119-122